FDA Approves New Therapy for Dravet Syndrome

The U.S. Food and Drug Administration approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting seizures despite medical treatment.

source https://www.pharmatutor.org/pharma-news/2020/fda-approves-new-therapy-for-dravet-syndrome